Company Overview and News

 
U.S. Equities See Record Outflows: ETFs in Focus

2018-04-04 zacks
U.S. equity funds witnessed outflows of about $10.3 billion in March, per an etf.com article, citing FactSet data. Investors pulled out $22.1 billion of large-cap focused funds. The outflows chart was led by SPDR S&P 500 ETF Trust (SPY - Free Report) and iShares Core S&P 500 ETF (IVV - Free Report) , which witnessed a respective $12.2 billion and $9.8 billion in outflow in March.
Upvote Downvote

 
Q1 ETF Asset Report: Developed Markets Win, High-Yield Loses

2018-03-29 zacks
The markets were more tensed than relaxed in the first quarter of 2018. Increasing inflationary expectations and rising rate fears pushed up bond yields and spurred equity sell-offs in late January and early February. Then, Trump-induced trade fear (thanks to his announcement of import tariffs) and a tech rout in March did the rest of the damage (read: 5 Reason Why FANG ETFs Lost Their Charm in March).
Upvote Downvote

1
Trust The Process And Boldly Buy Stocks Into Trade War Fear

2018-03-25 seekingalpha
The Fed meeting, and commensurate fear, are out of the way now and the result was nowhere near as costly to capital as the market feared.
Upvote Downvote

 
3 Small-Cap ETFs Experiencing High Inflows

2018-03-06 zacks
The S&P 500 entered correction territory in early February, as it declined more than 10% from the record high set in January. Robust wage growth and jobs data introduced fears of inflation making a comeback and led investors to bet on aggressive rate hikes.
Upvote Downvote

 
Inflation Watch: The Good, The Bad & The Ugly

2018-03-06 seekingalpha
Federal Reserve Chairman Powell raised market concerns about inflation and the Fed funds rate trajectory, before later easing them, through his two-day testimony before congressional panels last week.
Upvote Downvote

1
Inside February ETF Asset Report

2018-03-02 zacks
February 2018 will be remembered for the brake that the Trump Rally hit after a long and smooth journey. Several market watchers persistently warned of overvaluation and investors have showed amazing patience so far. But the U.S. market crashed to start February.
Upvote Downvote

 
SPDR Gold Trust - This Week's Abnormal Behavior And Forward Factors Explained

2018-03-02 seekingalpha
Precious metals and the SPDR Gold Trust security came under pressure this week alongside U.S. equities, failing as a hedge against such risk.
Upvote Downvote

 
Keep Your Eye On The Ball, Aka The Economy, Stupid

2018-02-27 seekingalpha
A recent economic data point provided important insight for investors, and I believe serves to refocus the market on what’s important.
Upvote Downvote

 
The S&P To The Rescue For Walmart

2018-02-22 seekingalpha
The 15 point drop in the S&P 500 (NYSE:SPY) yesterday was mainly due to the soft earnings report from Walmart the previous day and more sustained weakness in the bond market. The market didn't like Walmart's (NYSE:WMT) slow down in eCommerce growth, although management is still guiding 40% growth in this channel in the coming fiscal year. I stated in a recent article that it is going to take Walmart some time in eCommerce before really seeing better profit margins.
Upvote Downvote

 
Why Gold Failed As A Hedge Against This Stock Correction

2018-02-15 seekingalpha
Gold and silver prices failed as a hedge against the recent stock market correction, in my opinion, because of U.S. dollar appreciation.
Upvote Downvote

 
Markets Wobble. What You Should Do.

2018-02-11 seekingalpha
Crash. Turmoil. Plunge. Rout. These are just some of the words used to describe what's happened in markets in the past week or two. I'll use a less dramatic description. It's a wobble… at least, so far. Plus, it's a timely reminder of why I recommend investors should have a relatively cautious portfolio allocation in current markets. Let's look at what's been going on, and what to do about it.
Upvote Downvote

 
Stocks Are Expressing Fear Of The Fed, Not Inflation, And The Fix Is Easy

2018-02-10 seekingalpha
Action in the value of the U.S. dollar is telling me something about this market correction.
Upvote Downvote

 
The Stock Market Correction: Your Guide And Actionable Advice

2018-02-08 seekingalpha
The market correction and volatility are opening up opportunity, though stocks probably have a ceiling in place into the March Fed meeting.
Upvote Downvote

 
Here's How To Tack The Correction For The S&P 500 Using Two Daily Charts

2018-02-07 seekingalpha
The daily chart for the S&P 500 ETF (Spiders) does not reflect overnight volatility even though it can be traded after hours and pre-market.
Upvote Downvote

 
January ETF Asset Report: S&P 500 Wins, High-Yield Loses

2018-02-02 zacks
The month of January was all about Trump bump, cheering the tax reform, reassuring earnings, global economic growth and rising Treasury bond yields. Overall, markets remained upbeat though equities slipped at the end (read: Is it Time to Buy the Dip with ETFs?).
Upvote Downvote

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 78462F103